An anonymous director reports
CANNTRUST VOLUNTARY HOLD ON PRODUCT SALES AND FORMATION OF INDEPENDENT SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS
Canntrust Holdings Inc. has implemented a voluntary hold on sale and shipment of all cannabis products as a precaution while Health Canada visits and reviews its Vaughan, Ont., manufacturing facility.
Canntrust placed a hold on medical sales through its customer service line and on-line as of 11:59 p.m. on July 10.
Canntrust is working closely with the regulator through the review process, and expects to provide further detail of the duration of the hold and other developments as they become available.
Patients and consumers who have questions about Canntrust products can contact the company's customer care team at email@example.com and 1-855-RX4-CANN.
At this time, the impact of these matters on Canntrust's financial results are unknown until the regulatory review process is complete.
Independent special committee of the board of directors
Canntrust has also announced that a special committee of the board of directors has been established. The special committee comprises independent members of the board of directors. The purpose of the special committee is to investigate this matter in its entirety.
Canntrust is a federally regulated licensed producer of medical and recreational cannabis in Canada. Founded by pharmacists, Canntrust brings more than 40 years of pharmaceutical and health care experience to the medical cannabis industry, and serves more than 72,000 medical patients with its dried, extract and capsule products.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.